Literature DB >> 7775629

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.

W Oelkers1, J M Foidart, N Dombrovicz, A Welter, R Heithecker.   

Abstract

Combined hormonal oral contraceptives (OCs) may lead to a mild rise in blood pressure and body weight. In rare instances, large increments in blood pressure are measured. We investigated the effect of a combination of ethinyl estradiol (EE) plus a progestogen with antimineralocorticoid, i.e. natriuretic, properties [Drospirenone (DRSP)] on body weight, blood pressure, the renin-aldosterone system, atrial natriuretic factor, plasma lipids, and glucose tolerance. It is anticipated that this will lead to the development of an OC that does not raise body weight or blood pressure. Four groups of 20 women each received 30 micrograms EE plus 3 mg DRSP (group A), 20 micrograms EE plus 3 mg DRSP (group B), 15 micrograms EE plus 3 mg DRSP (group C), and, as a control OC, 30 micrograms EE plus 150 micrograms levonorgestrel (Microgynon, Schering; group D) for 6 months. During the OC-free control cycles before and after treatment and throughout treatment, the target parameters were measured. Between the pretreatment cycle and the sixth treatment cycle, mean body weight fell by 0.8 to 1.7 kg in groups A, B, and C (P < 0.05 vs. D), whereas it rose by 0.7 kg in group D. Systolic and diastolic blood pressures fell by 1-4 mm Hg in groups A, B, and C (significant for A and C vs. D) and increased by 1-2 mm Hg in group D. Renin substrate rose equally in all groups (P < 0.05), whereas PRA and plasma aldosterone rose significantly only in the DRSP groups, presumably due to sodium loss. In the DRSP groups, high density lipoprotein cholesterol rose (P < 0.05), in contrast to group D. Low density lipoprotein cholesterol fell slightly (P > 0.05), whereas triglyceride levels showed a stronger increase in the DRSP groups (P < 0.05) than in group D. All groups attained good cycle control; group A had the best. Side-effects were minimal. To our knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure. It may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.

Entities:  

Keywords:  Biology; Blood Pressure--changes; Body Weight--changes; Carbohydrate Metabolic Effects; Clinical Research; Contraception; Contraception Research; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods--pharmacodynamics; Contraceptive Methods--side effects; Developed Countries; Europe; Family Planning; Germany; Glucose Metabolism Effects; Hemic System; Lipid Metabolic Effects; Lipids; Metabolic Effects; Oral Contraceptives, Combined--pharmacodynamics; Oral Contraceptives, Combined--side effects; Oral Contraceptives--pharmacodynamics; Oral Contraceptives--side effects; Physiology; Research Methodology; Research Report; Western Europe

Mesh:

Substances:

Year:  1995        PMID: 7775629     DOI: 10.1210/jcem.80.6.7775629

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

Review 1.  Hormonal replacement therapy.

Authors:  Regine Sitruk-Ware
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

3.  Long-term effects of oral contraceptives on the prevalence of diabetes in post-menopausal women: 2007-2012 KNHANES.

Authors:  Sung-Woo Kim; Jae-Han Jeon; Won-Kee Lee; Sungwoo Lee; Jung-Guk Kim; In-Kyu Lee; Keun-Gyu Park
Journal:  Endocrine       Date:  2016-05-09       Impact factor: 3.633

Review 4.  Choosing the best contraceptive method for the adult with congenital heart disease.

Authors:  Candice K Silversides; Mathew Sermer; Samuel C Siu
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

5.  Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors:  Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

6.  Oral contraceptive use as a determinant of plasma concentrations of perfluoroalkyl substances among women in the Norwegian Mother and Child Cohort (MoBa) study.

Authors:  Elise L Rush; Alison B Singer; Matthew P Longnecker; Line S Haug; Azemira Sabaredzovic; Elaine Symanski; Kristina W Whitworth
Journal:  Environ Int       Date:  2017-12-20       Impact factor: 9.621

7.  Influence of oral contraceptives on lipid profile and paraoxonase and commonly hepatic enzymes activities.

Authors:  Katarzyna Kowalska; Milena Ściskalska; Anna Bizoń; Mariola Śliwińska-Mossoń; Halina Milnerowicz
Journal:  J Clin Lab Anal       Date:  2017-03-09       Impact factor: 2.352

Review 8.  Drospirenone, a new progestogen, for postmenopausal women with hypertension.

Authors:  Madhavi Mallareddy; Vladimir Hanes; William B White
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 9.  Contraceptive hormone use and cardiovascular disease.

Authors:  Chrisandra L Shufelt; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

10.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.

Authors:  A van Hylckama Vlieg; F M Helmerhorst; J P Vandenbroucke; C J M Doggen; F R Rosendaal
Journal:  BMJ       Date:  2009-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.